U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Cogwheel rigidity

MedGen UID:
57469
Concept ID:
C0151564
Sign or Symptom
Synonyms: Cogwheel Rigidities; Cogwheel Rigidity; Rigidities, Cogwheel; Rigidity, Cogwheel
SNOMED CT: Cogwheel rigidity (55630000); Cogwheel muscle rigidity (55630000)
 
HPO: HP:0002396

Definition

A type of rigidity in which a muscle responds with cogwheellike jerks to the use of constant force in bending the limb (i.e., it gives way in little, repeated jerks when the muscle is passively stretched). [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • Cogwheel rigidity

Conditions with this feature

Early-onset parkinsonism-intellectual disability syndrome
MedGen UID:
208674
Concept ID:
C0796195
Disease or Syndrome
Waisman syndrome (WSMN) is an X-linked neurologic disorder characterized by delayed psychomotor development, impaired intellectual development, and early-onset Parkinson disease (summary by Wilson et al., 2014).
Deficiency of ferroxidase
MedGen UID:
168057
Concept ID:
C0878682
Disease or Syndrome
Aceruloplasminemia is characterized by iron accumulation in the brain and viscera. The clinical triad of retinal degeneration, diabetes mellitus (DM), and neurologic disease is seen in individuals ranging from age 30 years to older than 70 years. The neurologic findings of movement disorder (blepharospasm, grimacing, facial and neck dystonia, tremors, chorea) and ataxia (gait ataxia, dysarthria) correspond to regions of iron deposition in the brain. Individuals with aceruloplasminemia often present with anemia prior to onset of DM or obvious neurologic problems. Cognitive dysfunction including apathy and forgetfulness occurs in more than half of individuals with this condition.
Biotin-responsive basal ganglia disease
MedGen UID:
375289
Concept ID:
C1843807
Disease or Syndrome
Biotin-thiamine-responsive basal ganglia disease (BTBGD) may present in childhood, early infancy, or adulthood. The classic presentation of BTBGD occurs in childhood (age 3-10 years) and is characterized by recurrent subacute encephalopathy manifest as confusion, seizures, ataxia, dystonia, supranuclear facial palsy, external ophthalmoplegia, and/or dysphagia which, if left untreated, can eventually lead to coma and even death. Dystonia and cogwheel rigidity are nearly always present; hyperreflexia, ankle clonus, and Babinski responses are common. Hemiparesis or quadriparesis may be seen. Episodes are often triggered by febrile illness or mild trauma or stress. Simple partial or generalized seizures are easily controlled with anti-seizure medication. An early-infantile Leigh-like syndrome / atypical infantile spasms presentation occurs in the first three months of life with poor feeding, vomiting, acute encephalopathy, and severe lactic acidosis. An adult-onset Wernicke-like encephalopathy presentation is characterized by acute onset of status epilepticus, ataxia, nystagmus, diplopia, and ophthalmoplegia in the second decade of life. Prompt administration of biotin and thiamine early in the disease course results in partial or complete improvement within days in the childhood and adult presentations, but most with the infantile presentation have had poor outcome even after supplementation with biotin and thiamine.
Spinocerebellar ataxia type 21
MedGen UID:
375311
Concept ID:
C1843891
Disease or Syndrome
Spinocerebellar ataxia-21 (SCA21) is an autosomal dominant neurologic disorder characterized by onset in the first decades of life of slowly progressive cerebellar ataxia, which is associated with cognitive impairment in most patients (summary by Delplanque et al., 2014). For a general discussion of autosomal dominant spinocerebellar ataxia, see SCA1 (164400).
Spinocerebellar ataxia type 19/22
MedGen UID:
339504
Concept ID:
C1846367
Disease or Syndrome
Spinocerebellar ataxia-19 (SCA19) is an autosomal dominant disorder characterized by progressive cerebellar ataxia with a variable age of onset (age 2 years to late adulthood). Other neurologic manifestations include developmental delay and cognitive impairment; movement disorders including myoclonus, dystonia, rigidity, and bradykinesia; and seizures. For a general discussion of autosomal dominant spinocerebellar ataxia, see SCA1 (164400).
Dystonia 5
MedGen UID:
342121
Concept ID:
C1851920
Disease or Syndrome
GTP cyclohydrolase 1-deficient dopa-responsive dystonia (GTPCH1-deficient DRD) is characterized by childhood-onset dystonia and a dramatic and sustained response to low doses of oral administration of levodopa. This disorder typically presents with gait disturbance caused by foot dystonia, later development of parkinsonism, and diurnal fluctuation of symptoms (aggravation of symptoms toward the evening and alleviation of symptoms in the morning after sleep). Initial symptoms are often gait difficulties attributable to flexion-inversion (equinovarus posture) of the foot. Occasionally, initial symptoms are arm dystonia, postural tremor of the hand, or slowness of movements. Brisk deep-tendon reflexes in the legs, ankle clonus, and/or the striatal toe (dystonic extension of the big toe) are present in many affected individuals. In general, gradual progression to generalized dystonia is observed. Intellectual, cerebellar, sensory, and autonomic disturbances generally do not occur.
Autosomal recessive juvenile Parkinson disease 2
MedGen UID:
401500
Concept ID:
C1868675
Disease or Syndrome
Parkin type of early-onset Parkinson disease (PARK-Parkin) is characterized by the cardinal signs of Parkinson disease (PD): bradykinesia, resting tremor, and rigidity. The median age at onset is 31 years (range: 3-81 years). The disease is slowly progressive: disease duration of more than 50 years has been reported. Clinical findings vary; hyperreflexia is common. Lower-limb dystonia may be a presenting sign and cognitive decline appears to be no more frequent than in the general population. Dyskinesia as a result of treatment with levodopa frequently occurs.
X-linked parkinsonism-spasticity syndrome
MedGen UID:
813052
Concept ID:
C3806722
Disease or Syndrome
A rare genetic neurological disorder with characteristics of parkinsonian features (including resting or action tremor, cogwheel rigidity, hypomimia and bradykinesia) associated with variably penetrant spasticity, hyperactive deep tendon reflexes and Babinski sign. There is evidence this disease is caused by hemizygous mutation in the ATP6AP2 gene on chromosome Xp11.
Developmental and epileptic encephalopathy, 37
MedGen UID:
934737
Concept ID:
C4310770
Disease or Syndrome
Developmental and epileptic encephalopathy-37 (DEE37) is an autosomal recessive epileptic-dyskinetic neurologic disorder characterized by the onset of intractable seizures or abnormal movements in the first months or years of life. Patients typically have normal or only mildly delayed development in early infancy, but then show developmental regression and stagnation after the onset of seizures, which can occur between about 6 months to 2 years of age. In addition to epileptic encephalopathy, affected individuals also manifest a hyperkinetic movement disorder with choreoathetosis, spasticity, and rigidity. There is severely impaired intellectual development and function, loss of verbal skills with absent speech, and impaired volitional movements (summary by Madeo et al., 2016). For a general phenotypic description and a discussion of genetic heterogeneity of DEE, see 308350.
Microcephaly, cataracts, impaired intellectual development, and dystonia with abnormal striatum
MedGen UID:
1648355
Concept ID:
C4748984
Disease or Syndrome
The MCIDDS syndrome is characterized by microcephaly and growth retardation, congenital cataracts, impaired intellectual development with attention deficit-hyperactivity disorder, and dystonia, with striatal thinning seen on MRI (Al-Owain et al., 2013).
Neurodevelopmental disorder with or without variable movement or behavioral abnormalities
MedGen UID:
1802087
Concept ID:
C5676908
Disease or Syndrome
Neurodevelopmental disorder with or without variable movement or behavioral abnormalities (NEDMAB) is an autosomal dominant disorder characterized by mildly to severely impaired intellectual development and, in some patients, movement abnormalities consisting of tremors, cerebellar ataxia, or extrapyramidal symptoms. Movement abnormalities have onset in childhood or adolescence. Other variable features include autism spectrum disorder or autistic features and epilepsy.
Classic dopamine transporter deficiency syndrome
MedGen UID:
1814585
Concept ID:
C5700336
Disease or Syndrome
SLC6A3-related dopamine transporter deficiency syndrome (DTDS) is a complex movement disorder with a continuum that ranges from classic early-onset DTDS (in the first 6 months) to atypical later-onset DTDS (in childhood, adolescence, or adulthood). Classic DTDS. Infants typically manifest nonspecific findings (irritability, feeding difficulties, axial hypotonia, and/or delayed motor development) followed by a hyperkinetic movement disorder (with features of chorea, dystonia, ballismus, orolingual dyskinesia). Over time, affected individuals develop parkinsonism-dystonia characterized by bradykinesia (progressing to akinesia), dystonic posturing, distal tremor, rigidity, and reduced facial expression. Limitation of voluntary movements leads to severe motor delay. Episodic status dystonicus, exacerbations of dystonia, and secondary orthopedic, gastrointestinal, and respiratory complications are common. Many affected individuals appear to show relative preservation of intellect with good cognitive development. Atypical DTDS. Normal psychomotor development in infancy and early childhood is followed by later-onset manifestations of parkinsonism-dystonia with tremor, progressive bradykinesia, variable tone, and dystonic posturing. The long-term outcome of this form is currently unknown.

Professional guidelines

PubMed

Caproni S, Colosimo C
Clin Geriatr Med 2020 Feb;36(1):13-24. Epub 2019 Sep 17 doi: 10.1016/j.cger.2019.09.014. PMID: 31733693
LaFaver K, Espay AJ
Semin Neurol 2017 Apr;37(2):228-232. Epub 2017 May 16 doi: 10.1055/s-0037-1601487. PMID: 28511263
Jankovic J
J Neurol Neurosurg Psychiatry 2011 Dec;82(12):1300-3. Epub 2011 Sep 20 doi: 10.1136/jnnp-2011-300876. PMID: 21933950

Recent clinical studies

Etiology

Holtback C, Welin C, Fu M, Thunström E, Rosengren A, Lappas G, Hansson PO
Acta Neurol Scand 2022 Mar;145(3):305-313. Epub 2021 Nov 17 doi: 10.1111/ane.13557. PMID: 34791639
Eriguchi M, Iida K, Ikeda S, Osoegawa M, Nishioka K, Hattori N, Nagayama H, Hara H
Intern Med 2019 Jul 1;58(13):1935-1938. Epub 2019 Feb 25 doi: 10.2169/internalmedicine.2028-18. PMID: 30799335Free PMC Article
Jankovic J
J Neurol Neurosurg Psychiatry 2011 Dec;82(12):1300-3. Epub 2011 Sep 20 doi: 10.1136/jnnp-2011-300876. PMID: 21933950
Lewis R, Bagnall AM, Leitner M
Cochrane Database Syst Rev 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. PMID: 16034864Free PMC Article
Burns JM, Galvin JE, Roe CM, Morris JC, McKeel DW
Neurology 2005 Apr 26;64(8):1397-403. doi: 10.1212/01.WNL.0000158423.05224.7F. PMID: 15851730

Diagnosis

Salehi P, Clark M, Pinzon J, Patil A
Am J Emerg Med 2022 Feb;52:267.e1-267.e3. Epub 2021 Jul 22 doi: 10.1016/j.ajem.2021.07.038. PMID: 34334283
Caproni S, Colosimo C
Clin Geriatr Med 2020 Feb;36(1):13-24. Epub 2019 Sep 17 doi: 10.1016/j.cger.2019.09.014. PMID: 31733693
LaFaver K, Espay AJ
Semin Neurol 2017 Apr;37(2):228-232. Epub 2017 May 16 doi: 10.1055/s-0037-1601487. PMID: 28511263
Thenganatt MA, Jankovic J
Handb Clin Neurol 2016;139:259-262. doi: 10.1016/B978-0-12-801772-2.00022-9. PMID: 27719845
Zhang Z, Moreno A
J Addict Med 2014 Nov-Dec;8(6):474-5. doi: 10.1097/ADM.0000000000000073. PMID: 25187976

Therapy

Sharma KD, Colangelo T, Mills A
Int J Clin Pharmacol Ther 2022 Apr;60(4):184-187. doi: 10.5414/CP204068. PMID: 35102822
Zhang Z, Moreno A
J Addict Med 2014 Nov-Dec;8(6):474-5. doi: 10.1097/ADM.0000000000000073. PMID: 25187976
Buckman F
BMJ Case Rep 2013 Apr 22;2013 doi: 10.1136/bcr-2013-009407. PMID: 23608871Free PMC Article
Jankovic J
J Neurol Neurosurg Psychiatry 2011 Dec;82(12):1300-3. Epub 2011 Sep 20 doi: 10.1136/jnnp-2011-300876. PMID: 21933950
Shults CW
Arch Neurol 2003 Dec;60(12):1680-4. doi: 10.1001/archneur.60.12.1680. PMID: 14676041

Prognosis

Holtback C, Welin C, Fu M, Thunström E, Rosengren A, Lappas G, Hansson PO
Acta Neurol Scand 2022 Mar;145(3):305-313. Epub 2021 Nov 17 doi: 10.1111/ane.13557. PMID: 34791639
Kojima G, Tatsuno BK, Inaba M, Velligas S, Masaki K, Liow KK
Hawaii J Med Public Health 2013 Apr;72(4):136-9. PMID: 23795314Free PMC Article
Jankovic J
J Neurol Neurosurg Psychiatry 2011 Dec;82(12):1300-3. Epub 2011 Sep 20 doi: 10.1136/jnnp-2011-300876. PMID: 21933950
Segawa M
Brain Dev 2000 Sep;22 Suppl 1:S65-80. doi: 10.1016/s0387-7604(00)00148-0. PMID: 10984664
Shriqui CL
Can J Psychiatry 1995 Sep;40(7 Suppl 2):S38-48. doi: 10.1177/070674379504007s03. PMID: 8564916

Clinical prediction guides

Pei Y, Mansouri M, Zallek CM, Hsiao-Wecksler ET
IEEE Trans Neural Syst Rehabil Eng 2023;31:3320-3330. Epub 2023 Aug 21 doi: 10.1109/TNSRE.2023.3304951. PMID: 37578921
Holtback C, Welin C, Fu M, Thunström E, Rosengren A, Lappas G, Hansson PO
Acta Neurol Scand 2022 Mar;145(3):305-313. Epub 2021 Nov 17 doi: 10.1111/ane.13557. PMID: 34791639
Lewis R, Bagnall AM, Leitner M
Cochrane Database Syst Rev 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. PMID: 16034864Free PMC Article
Sadek AH, Rauch R, Schulz PE
Int J Toxicol 2003 Sep-Oct;22(5):393-401. doi: 10.1177/109158180302200511. PMID: 14555414
Shriqui CL
Can J Psychiatry 1995 Sep;40(7 Suppl 2):S38-48. doi: 10.1177/070674379504007s03. PMID: 8564916

Recent systematic reviews

Lewis R, Bagnall AM, Leitner M
Cochrane Database Syst Rev 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. PMID: 16034864Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...